Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 10—October 2009

Letter

Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists

Reinout M. SwartComments to Author , Jakko van Ingen, Dick van Soolingen, Rob Slingerland, Willem D.H. Hendriks, and Jan G. den Hollander
Author affiliations: Maasstad Ziekenhuis Rotterdam, Rotterdam, the Netherlands (R.M. Swart, R. Slingerland, W.D.H. Hendriks, J.G. den Hollander); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (J. van Ingen, D. van Soolingen).

Main Article

Table

Antimicrobial drug susceptibility test results for Mycobacterium haemophilum isolate from rheumatoid arthritis patient and other M. haemophilum isolates*

Antimicrobial
drug Case report
RIVM historic data (n = 49)
Classification MIC, mg/L % Susceptible % Resistant
Isoniazid Resistant 10 0 100
Rifampin Susceptible 0.2 4 96
Ethambutol Resistant 20 0 100
Streptomycin Susceptible <1.0 35 65
Cycloserine Susceptible 50 78 22
Prothionamide Susceptible <1.0 61 39
Amikacin Resistant 10 29 71
Ciprofloxacin Resistant 4.0 88 12
Clofazimine Susceptible <0.5 92 8
Clarithromycin Susceptible <2.0 94 6
Rifabutin Susceptible <0.2 96 4

*All isolates submitted to the Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment (RIVM), the Netherlands, January 2000–January 2007. Before January 2004, strains tested were identified by 16S rDNA gene sequencing; after January 2004, strains were identified by the Inno-LiPA assay (Innogenetics, Ghent, Belgium).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO